U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C7H14NO5P
Molecular Weight 223.1635
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELFOTEL

SMILES

OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1

InChI

InChIKey=LPMRCCNDNGONCD-RITPCOANSA-N
InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1

HIDE SMILES / InChI
(+)-selfotel ((+)-CGS-19755) is an enantiomer of selfotel, a competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptors. The inhibition of NMDA-evoked ACh release from rat striatal slices is stereospecific, with the (+)-enantiomer less potent than the (-)-enantiomer.

CNS Activity

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20676 ng/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
31622 ng × h/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Other AEs: Agitation, Confusion...
Other AEs:
Agitation (66.7%)
Confusion (50%)
Delirium (33.3%)
Paranoid reaction (50%)
Coordination abnormal (16.7%)
Aphasia (16.7%)
Hallucination (50%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Aphasia 16.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Coordination abnormal 16.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Delirium 33.3%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Confusion 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Hallucination 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Paranoid reaction 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Agitation 66.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist.
1988 Jul
Glutamatergic antagonism: effects on lidocaine-induced seizures in the rat.
1994 Oct
Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine.
1999 May
The 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Tromso, Norway, 13-17 June 2001.
2001 Aug
A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke.
2001 Feb 23
Regional distribution and pharmacological characteristics of [3H]N-acetyl-aspartyl-glutamate (NAAG) binding sites in rat brain.
2001 Jan
Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog.
2001 Nov 16
Glutamate AMPA receptor antagonist treatment for ischaemic stroke.
2002
Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity.
2002
Stroke: trial by jury.
2003
Glutamate receptor antagonists modulate heat shock protein response in focal brain ischemia.
2003 Mar
Lessons from epidemiologic studies in clinical trials of traumatic brain injury.
2004
Nicotine exerts a permissive role on NMDA receptor function in hippocampal noradrenergic terminals.
2004 Jul
The rise and fall of NMDA antagonists for ischemic stroke.
2004 Mar
Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels.
2004 Oct
Acute nociceptive somatic stimulus sensitizes neurones in the spinal cord to colonic distension in the rat.
2004 Oct 1
Cerebral perfusion pressure and risk of brain hypoxia in severe head injury: a prospective observational study.
2005
Cognitive effects of dopaminergic and glutamatergic blockade in nucleus accumbens in pigeons.
2005 Aug
Homocysteine, a risk factor for atherosclerosis, biphasically changes the endothelial production of kynurenic acid.
2005 Jul 11
Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity.
2005 Jun
The NMDA receptor complex: a long and winding road to therapeutics.
2005 Mar
Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia.
2005 Sep
Severe brain injury ICU outcomes are associated with Cranial-Arterial Pressure Index and noninvasive Bispectral Index and transcranial oxygen saturation: a prospective, preliminary study.
2006
Glutamate receptors in neuroinflammatory demyelinating disease.
2006
The NMDA receptor antagonist CGS 19755 disrupts recovery following cerebellar lesions.
2006
Some prognostic models for traumatic brain injury were not valid.
2006 Feb
Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons.
2006 Mar
NMDA receptor activity in learning spatial procedural strategies II. The influence of cerebellar lesions.
2006 Oct 16
NMDA receptor activity in learning spatial procedural strategies I. The influence of hippocampal lesions.
2006 Oct 16
Acute D2/D3 dopaminergic agonism but chronic D2/D3 antagonism prevents NMDA antagonist neurotoxicity.
2006 Sep 15
Intracranial pressure monitoring in intensive care: clinical advantages of a computerized system over manual recording.
2007
Increased cerebral oxygen consumption in Eker rats and effects of N-methyl-D-aspartate blockade: Implications for autism.
2007 Aug 15
Repeated treatment with N-methyl-d-aspartate antagonists in neonatal, but not adult, rats causes long-term deficits of radial-arm maze learning.
2007 Sep 12
Risks associated with magnetic resonance imaging and cervical collar in comatose, blunt trauma patients with negative comprehensive cervical spine computed tomography and no apparent spinal deficit.
2008
Pharmacology of traumatic brain injury: where is the "golden bullet"?
2008 Nov-Dec
Molecular mechanisms of traumatic brain injury: the missing link in management.
2009 Feb 2
NMDA-mediated modulation of dopamine release is modified in rat prefrontal cortex and nucleus accumbens after chronic nicotine treatment.
2009 Jan
Cerebral vasospasm following traumatic subarachnoid hemorrhage.
2009 Nov
Resistin is associated with mortality in patients with traumatic brain injury.
2010
Integrative emphases on intimate, intrinsic propensity/pathological processes--causes of self recovery limits and also, subtle related targets for neuroprotectionl pleiotropicity/multimodal actions, by accessible therapeutic approaches--in spinal cord injuries.
2010 Jul-Sep
Patents

Patents

Sample Use Guides

Two pivotal phase 3 ischemic stroke trials tested the hypothesis, by double-blind, randomized, placebo-controlled parallel design, that a single intravenous 1.5 mg/kg dose of Selfotel, administered within 6 hours of stroke onset, would improve functional outcome at 90 days, defined as the proportion of patients achieving a Barthel Index score of >/=60. The trials were performed in patients aged 40 to 85 years with acute ischemic hemispheric stroke and a motor deficit.
Route of Administration: Intravenous
In Vitro Use Guide
Selfotel (CGS 19755 [cis-4-phosphonomethyl-2-piperidine carboxylic acid]) was found to be a potent, stereospecific inhibitor of N-methyl-D-aspartate (NMDA)-evoked, but not KCl-evoked, [3H] acetylcholine release from slices of the rat striatum. The concentration-response curve to NMDA was shifted to the right by CGS 19755 (pA2 = 5.94), suggesting a competitive interaction with NMDA-type receptors.
Name Type Language
SELFOTEL
INN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
SELFOTEL [USAN]
Common Name English
CPDD-0027
Code English
Selfotel [WHO-DD]
Common Name English
CGS-19755
Code English
SELFOTEL [MART.]
Common Name English
CIS-4-(PHOSPHONOMETHYL)-2-PIPERIDINE CARBOXYLIC ACID
Systematic Name English
2-PIPERIDINECARBOXYLIC ACID, 4-(PHOSPHONOMETHYL)-, CIS-
Common Name English
CGS 19755
Code English
selfotel [INN]
Common Name English
GNF-PF-157
Code English
2-PIPERIDINECARBOXYLIC ACID, 4-(PHOSPHONOMETHYL)-, (2R,4S)-REL-
Systematic Name English
Classification Tree Code System Code
WIKIPEDIA NMDA receptor antagonist
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
NCI_THESAURUS C1509
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
Code System Code Type Description
CAS
110347-85-8
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
FDA UNII
4VGJ4A41L2
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
INN
6843
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
USAN
CC-92
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
NCI_THESAURUS
C152322
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
WIKIPEDIA
SELFOTEL
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
ChEMBL
CHEMBL39664
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID5045675
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
EVMPD
SUB10476MIG
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
MESH
C053672
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
PUBCHEM
68736
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY
SMS_ID
100000084108
Created by admin on Sat Dec 16 15:51:20 GMT 2023 , Edited by admin on Sat Dec 16 15:51:20 GMT 2023
PRIMARY